Please login to the form below
neurological disorders
This page shows the latest neurological disorders news and features for those working in and with pharma, biotech and healthcare.
Pfizer to acquire Biohaven in deal worth over $11bn
Today’s announcement builds on our legacy of delivering breakthroughs for patients living with complex pain disorders and diseases that disproportionately impact women,” said Nick Lagunowich, global president at Pfizer Internal ... R&D company is
Latest news
-
Biogen pays Ionis $60m for licence to develop ASO for spinal muscular atrophy
Biogen and Ionis have a broad strategic collaboration to develop novel therapies to treat neurological disorders. ... BIIB115/ION306 represents another example of our productive collaboration with Biogen to discover and develop medicines that have
-
Five years needed to confirm the benefit of Aduhelm
approximately half of the time that the FDA provided as part of the accelerated approval,” said Dr Marwan Sabbagh, professor of neurology, Alzheimer's and memory disorders at the Barrow Neurological
-
Biogen reveals new data for MS therapies Tysabri and Vumerity
Researchers analysed patient-reported data on 12 different domains on the Neuro-QoL (Quality of Life in Neurological Disorders) questionnaire to ‘better understand clinically meaningful quality of life benefits’ following Tysabri
-
Roche, Genentech partner with The Weill Neurohub on ten-year neuroscience collaboration
At Genentech and Roche, we are strongly committed to discovering and developing breakthrough medicines to help improve the lives of people living with neurological disorders, which are some of the most ... We are excited to join forces with The Weill
-
Pfizer, Sanofi and others set to increase US drug prices in 2021
Generic drugmaker Teva Pharmaceuticals has also raised the prices on 15 drugs, including rare neurological disorders drug Austedo (deutetrabenazine), asthma steroid Qvar (beclometasone) and more.
More from news
Approximately 2 fully matching, plus 47 partially matching documents found.
Latest Intelligence
-
Pharma deals during December 2012
an upfront of $30m, to discover and co-develop antisense drugs to treat three neurological or neuromuscular disorders.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Bedrock Group strengthens its senior team
Derek has a wealth of expertise in a wide range of therapy areas including neurological disorders, rare diseases, diabetes, metabolic disorders, immunology, endocrinology, oncology, and medical devices.
-
Lucid Group welcomes three new graduates ahead of the 2020 Futures Academy
Tom’s experience lies in oncology, immunology and neurological disorders. During his studies, Tom also worked in the chemicals industry as an information scientist for a regulatory compliance company.
-
Diagnosing the lag in neuropsychiatric treatments
Neurological and psychiatric disorders (collectively known as neuropsychiatric disorders), such as Alzheimer’s disease and schizophrenia can affect any part of the brain or nervous system function. ... So why don’t doctors look at the biological
-
How can pharma help doctors in treating neurological disorders?
The large number of treatments that are now available to treat neurological disorders, such as multiple sclerosis (MS) and Parkinson’s disease, and the complex nature of these medications, are key
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- Eli Lilly to make bebtelovimab commercially available to US states from August
- ONS records a continued fall in UK COVID-19 infections
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Engaging KOLs and Gaining Insights in Pharma's New Normal
- That ‘don’t’ impress me much
- Bristol Myers Squibb and GentiBio in $1.9bn deal to develop IBD therapies
- Novartis’ Pluvicto receives MHRA marketing authorisation to treat advanced prostate cancer
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- ONS data reveals significant decrease in COVID-19 antibodies
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
- How the Royal Society’s EiR programme can help to drive UK innovation
- ...
